Clinical Trials
579
63 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1875
Active, not recruiting
30
5.2%
Completed
368
63.6%
Enrolling By Invitation
6
1.0%
Not yet recruiting
27
4.7%
Recruiting
57
9.8%
Suspended
3
0.5%
Terminated
39
6.7%
Unknown
31
5.3%
Withdrawn
18
3.1%
No approval data available
- New research demonstrates that Trikafta (elexacaftor/tezacaftor/ivacaftor) produces sustained reductions in key inflammatory markers in cystic fibrosis patients that persist through 2.5 years of treatment. - The PROMISE study found significant decreases in neutrophil elastase activity, calprotectin, IL-1β, and IL-8 within the first month of therapy that remained stable at 24-30 months. - Advanced 129Xenon MRI imaging shows greater sensitivity than traditional lung function tests in detecting treatment responses, particularly in pediatric patients with preserved lung function. - Patients with more severe disease (ppFEV1 <80%) and P. aeruginosa infections showed larger inflammatory reductions, suggesting personalized treatment benefits based on disease severity.
- A 12-month clinical trial involving 55 participants with Parkinson's disease dementia found that Ambroxol, a European cough medicine, was safe and well-tolerated while reaching therapeutic levels in the brain. - Psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol, and participants with high-risk GBA1 gene variants showed improved cognitive performance. - The blood marker GFAP, linked to brain damage, increased in the placebo group but stayed stable with Ambroxol treatment, suggesting potential brain protection. - The findings offer hope for a new treatment avenue for Parkinson's dementia, which affects about half of Parkinson's patients within 10 years of diagnosis.
- A multicenter clinical trial found that dapagliflozin combined with insulin reduced kidney disease risk and improved health outcomes in 98 adolescents with type 1 diabetes over 16 weeks. - The combination therapy demonstrated significant improvements including 8.8 ml/min reduction in glomerular filtration rate, 0.47% decrease in HbA1c, and 2.8 kg weight reduction compared to placebo. - Results showed similar safety profiles between treatment groups with only one mild case of diabetic ketoacidosis in the dapagliflozin group, suggesting the therapy could inform new early intervention strategies. - The study addresses a critical gap in adolescent diabetes research, as this age group is often underrepresented in clinical trials despite facing unique challenges with hormonal changes and treatment management.
- A large population-based study of 10,182 childhood cancer survivors found they face a five-fold higher risk of developing chronic kidney disease and hypertension compared to the general pediatric population. - The elevated risk emerges as early as the first year after completing cancer treatment and persists throughout long-term follow-up, with cumulative incidence reaching 20.85% in survivors versus 8.05% in controls. - Current international surveillance guidelines lack specific recommendations for kidney monitoring in childhood cancer survivors, highlighting an urgent need for evidence-based screening protocols. - The findings support treating childhood cancer survivors as a high cardiovascular disease risk group requiring primary and secondary prevention strategies throughout their lifetime.
- Individuals born preterm face significant educational disadvantages, with 17% lower college enrollment rates and 16% lower graduation rates, according to a comprehensive Canadian study of 2.4 million births. - Premature birth impacts long-term economic outcomes, with affected adults experiencing 6% lower average income and 2% lower employment rates, with effects most pronounced for those born at 24-27 weeks gestation. - New research reveals preterm birth is associated with increased mortality risk extending into adulthood, with the highest risk observed in early childhood and among those born before 28 weeks gestation.
• Two clinical trials demonstrated that using the SSPedi tool, which allows young cancer patients to report their symptoms, leads to improved supportive care and reduced side effects. • Patients aged 8-18 who regularly reported their symptoms experienced fewer cancer-related issues like fatigue and mood changes compared to those receiving standard care. • Integrating symptom screening with predefined care pathways is crucial for ensuring that healthcare providers can effectively respond to the needs identified by young patients. • The SSPedi tool is being integrated into major electronic health record systems, potentially facilitating the widespread adoption of pediatric patient-reported outcomes.
